• Markets
    • icon
  • Companies
ILA · ASX

Island Pharmaceuticals Ltd (ASX:ILA)

AU$0.078

 -0.001 (-1.266%)
ASX:Live
16/09/2024 12:09:30 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ILA Overview

ILA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ILA

Website

N/A

Telephone

N/A

Address

Description

Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. Its Isla101, a drug being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The company was founded by David Foster on May 25, 2020 and is headquartered in Camberwell, Australia.

ILA Price Chart

Key Stats

Market Cap

AU$10.02M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.09

Trade Value (12mth)

AU$2,400.00

1 week

2.6%

1 month

21.54%

YTD

-10.45%

1 year

0.09%

All time high

0.62

Key Fundamentals

EPS 3 yr Growth

29.90%

EBITDA Margin

N/A

Operating Cashflow

-$3m

Free Cash Flow Return

-192.20%

ROIC

-173.40%

Interest Coverage

-89.30

Quick Ratio

2.50

Other Data

Shares on Issue (Fully Dilluted)

98m

HALO Sector

Healthcare

Next Company Report Date

21-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ILA Announcements

Latest Announcements

Date Announcements

11 September 24

Binding LOI for proposed acquisition of Galidesivir

×

Binding LOI for proposed acquisition of Galidesivir

29 August 24

Preliminary Final Report

×

Preliminary Final Report

29 August 24

Annual Report to shareholders

×

Annual Report to shareholders

29 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

27 August 24

Phase 2a/b clinical trial update

×

Phase 2a/b clinical trial update

07 August 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

07 August 24

ISLA-101 Phase 2a/b clinical trial progresses

×

ISLA-101 Phase 2a/b clinical trial progresses

31 July 24

Quarterly Activities & Cashflow Report

×

Quarterly Activities & Cashflow Report

19 July 24

Resignation of Joint Company Secretary

×

Resignation of Joint Company Secretary

10 July 24

Investor Presentation - Bioshares

×

Investor Presentation - Bioshares

03 July 24

Non-binding term sheet signed with BioCryst

×

Non-binding term sheet signed with BioCryst

03 July 24

ISLA-101 Clinical Program Update

×

ISLA-101 Clinical Program Update

01 July 24

Trading Halt

×

Trading Halt

26 June 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

26 June 24

Change of Director Interest Notice - DF

×

Change of Director Interest Notice - DF

21 June 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

21 June 24

Change in substantial holding

×

Change in substantial holding

19 June 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

12 June 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

06 June 24

Notification regarding unquoted securities - ILA

×

Notification regarding unquoted securities - ILA

06 June 24

Piggy Back Options Closing Date Reminder

×

Piggy Back Options Closing Date Reminder

05 June 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

03 June 24

New data leads to proposed ISLA-101 Phase 2 efficiencies

×

New data leads to proposed ISLA-101 Phase 2 efficiencies

03 June 24

Investor Presentation

×

Investor Presentation

29 May 24

Application for quotation of securities - ILA

×

Application for quotation of securities - ILA

ILA Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.1 -8.4 1.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -127.9 -7.3 21.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -15.9 -35.1 -45.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.05 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.05 0.02 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.8 -58.7 -41.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 88 88 90 Lock Lock Lock
Basic m Lock Lock Lock Lock 88 88 90 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 3 4 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.3 -3.5 -41.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.3 -3.5 -41.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.6 -8.6 -1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -3 -3 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.1 -44.3 -17.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 5 2 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 5 2 3 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -5 -2 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 2 2 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 2 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.5 -58.7 -14.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -53.2 -138.1 -111.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -60.4 -158.5 -188.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -52.4 -95.3 -221.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -48.6 -92.7 -173.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -35.0 -88.8 -192.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A -323.1 -89.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 0.7 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -110.9 -111.9 -81.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 8.4 7.8 2.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.4 7.8 2.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 97.7 97.5 64.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -323.3 -1,026.6 -303.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -53.2 -138.1 -111.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -60.4 -158.5 -188.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -60.4 -158.5 -188.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ILA Shortsell

Frequently Asked Questions

The current share price of Island Pharmaceuticals Ltd (ILA:ASX) is AU$0.078.
The 52-week high share price for Island Pharmaceuticals Ltd (ILA:ASX) is AU$0.09.
The 52-week low share price for Island Pharmaceuticals Ltd (ILA:ASX)? is AU$0.05.
Island Pharmaceuticals Ltd (ILA:ASX) does not pay a dividend.
Island Pharmaceuticals Ltd (ILA:ASX) does not pay a dividend.
Island Pharmaceuticals Ltd (ILA:ASX) has a franking level of 0.0%.
Island Pharmaceuticals Ltd (ILA:ASX) is classified in the Healthcare.
The current P/E ratio for Island Pharmaceuticals Ltd (ILA:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.